Page 3 - Affimed News Today

Affimed (NASDAQ:AFMD – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the eight research firms that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 1 year target price among […]

Shares of Affimed (NASDAQ:AFMD – Get Free Report) have been assigned an average rating of “Moderate Buy” from the eight brokerages that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating on the company. The average 12-month price objective […]

Cantor Fitzgerald reaffirmed their overweight rating on shares of Affimed (NASDAQ:AFMD – Free Report) in a report published on Monday morning, Benzinga reports. The brokerage currently has a $7.00 price objective on the biopharmaceutical company’s stock. A number of other equities analysts also recently commented on the company. Berenberg Bank reissued a buy rating and […]

Research Analysts’ updated eps estimates for Monday, September 25th: Apple (NASDAQ:AAPL) had its overweight rating reaffirmed by analysts at Morgan Stanley. They currently have a $215.00 target price on the stock. ADT (NYSE:ADT) had its sector perform rating reiterated by analysts at Royal Bank of Canada. They currently have a $10.00 target price on the […]

Immuno-oncology company Affimed N.V. (AFMD) announced that the FDA has granted fast track designation to the combination of its innate cell engager (ICE) AFM13 with AlloNK for the potential treatment of relapsed/refractory (r/r) Hodgkin lymphoma (HL).

Affimed (NASDAQ:AFMD – Get Free Report)‘s stock had its “overweight” rating restated by equities researchers at Cantor Fitzgerald in a research note issued on Thursday, Benzinga reports. They currently have a $7.00 price target on the biopharmaceutical company’s stock. AFMD has been the subject of several other reports. HC Wainwright reaffirmed a “buy” rating and […]

Affimed (NASDAQ:AFMD – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the eight ratings firms that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 1-year target price among analysts […]

Affimed (NASDAQ:AFMD – Free Report) had its target price trimmed by Truist Financial from $8.00 to $6.00 in a report released on Friday morning, Marketbeat reports. They currently have a buy rating on the biopharmaceutical company’s stock. AFMD has been the topic of a number of other research reports. Berenberg Bank restated a buy rating […]

03.08.2023 - HEIDELBERG, Germany, Aug. 03, 2023 (GLOBE NEWSWIRE) - Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release second quarter ...

Affimed (NASDAQ:AFMD – Free Report) – Research analysts at Cantor Fitzgerald issued their FY2024 EPS estimates for Affimed in a note issued to investors on Tuesday, July 11th. Cantor Fitzgerald analyst L. Watsek forecasts that the biopharmaceutical company will post earnings of ($0.37) per share for the year. The consensus estimate for Affimed’s current full-year […]